Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

被引：25

作者：

Schjesvold, Fredrik ^{[1
,2
]}

Richardson, Paul G. ^{[3
]}

Facon, Thierry ^{[4
]}

Alegre, Adrian ^{[5
,6
]}

Spencer, Andrew ^{[7
]}

Jurczyszyn, Artur ^{[8
]}

Sunami, Kazutaka ^{[9
]}

Frenzel, Laurent ^{[10
]}

Min, Chang-Ki ^{[11
,12
]}

Guillonneau, Sophie ^{[13
]}

Lin, Peggy L. ^{[14
]}

Le-Guennec, Solenn ^{[15
]}

Campana, Frank ^{[16
]}

van de Velde, Helgi ^{[16
]}

Bensfia, Samira ^{[14
]}

Bringhen, Sara ^{[17
]}

机构：

[1] Oslo Univ Hosp, Oslo Myeloma Ctr, Oslo, Norway

[2] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Lille Univ Hosp, Lille, France

[5] Hosp Univ La Princesa, Madrid, Spain

[6] Hosp Quironsalud, Madrid, Spain

[7] Monash Univ, Alfred Hlth, Dept Clin Hematol, Melbourne, Vic, Australia

[8] Jagiellonian Univ, Coll Med, Dept Hematol, Krakow, Poland

[9] Natl Hosp Org Okayama Med Ctr, Dept Hematol, Okayama, Japan

[10] Hop Necker Enfants Malad, Paris, France

[11] Catholic Hematol Hosp, Dept Hematol, Seoul, South Korea

[12] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Leukemia Res Inst, Seoul, South Korea

[13] Sanofi CMO, Chilly Mazarin, France

[14] Sanofi Global Oncol, Cambridge, MA USA

[15] Sanofi R&D, Vitry Sur Seine, France

[16] Sanofi R&D, Cambridge, MA USA

[17] Univ Torino, Azienda Osped Univ Citta Salute & Sci Torino, Myeloma Unit, Div Hematol, Turin, Italy

来源：

HAEMATOLOGICA | 2021年 / 106卷 / 04期

关键词：

SAR650984;

D O I：

10.3324/haematol.2020.253450

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1182 / 1187

页数：6

共 50 条

[21] Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).
Richardson, Paul G.
Perrot, Aurore
San-Miguel, Jesus F.
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Sy.
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Zheng, Cheng
Dubin, Franck
Van de Velde, Helgi
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[22] Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
Richardson, Paul G.
Facon, Thierry
Bensinger, William I.
Leleu, Xavier
Campana, Frank
Mace, Sandrine
Chiron, Marielle
van de Velde, Helgi
Mikhael, Joseph
BLOOD CANCER JOURNAL, 2021, 11 (03)
[23] Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
Paul G. Richardson
Thierry Facon
William I. Bensinger
Xavier Leleu
Frank Campana
Sandrine Macé
Marielle Chiron
Helgi van de Velde
Joseph Mikhael
Blood Cancer Journal, 11
[24] Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)
Richardson, Paul G.
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Zheng, Cheng
Dubin, Franck
van de Velde, Helgi
Anderson, Kenneth C.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S423 - S424
[25] Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan
Nami Tagami
Michihiro Uchiyama
Kenshi Suzuki
Heigoroh Shirai
Takeshi Seto
Shinsuke Iida
International Journal of Hematology, 2025, 121 (4) : 476 - 482
[26] Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis
Moreau, Philippe
Perrot, Aurore
Dimopoulos, Meletios-Athanasios
Martin, Thomas
Facon, Thierry
Capra, Marcelo
Beksac, Meral
Armstrong, Nicole M.
Dubin, Franck
Mace, Sandrine
Risse, Marie-Laure
Tekle, Christina
Klippel, Zandra
Richardson, Paul G.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S484 - S484
[27] An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma
Piggin, Anna
Prince, H. Miles
EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (05) : 419 - 427
[28] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study (vol 23, pg 416, 2022)
Richardson, P. G.
Perrot, A.
San-Miguel, J.
LANCET ONCOLOGY, 2022, 23 (04): : E161 - E161
[29] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study (vol 23, pg 416, 2022)
Richardson, P. G.
Perrot, A.
San-Miguel, J.
LANCET ONCOLOGY, 2022, 23 (09): : E404 - E404
[30] Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis
Facon, Thierry
Moreau, Philippe
Martin, Thomas G.
Spicka, Ivan
Oriol, Albert
Koh, Youngil
Lim, Andrew
Mikala, Gabor
Rosinol, Laura
Yagci, Munci
Cavo, Michele
Yong, Kwee
Risse, Marie-Laure
Asset, Gaelle
Schwab, Sandrine
Martinez, Gracia
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S420 - S420

← 1 2 3 4 5 →